Den här hemsidan kräver JavaScript för att fungera tillfredsställande. Vänligen ändra dina inställningar eller använd en annan webläsare för att fortsätta.       

Du är nu på väg att lämna en GSK-hemsida

Denna länk leder till en hemsida som inte tillhör GSK. GSK tar inget ansvar för innehållet på tredje parts hemsidor.

Fortsätt

Tillbaka

Unit for Hours:H

Unit for Minutes: M

Filter redirection page URL: /content/cf-pharma/health-hcpportal/se_SE/hcp/home/events.html

Login overlay needed?:

Filter Tags:Terapiområde

Filter Tags values when filtered by all Tags:Alla terapiområden

OutofBox filter category name:Typ

Filter Reset all button text:Återställ

Filter Apply button text:Apply

Events registration success message: Registration successfull

Events registration failure message: Registration failure

Events un-registration success message: Un-Registration successfull

Events un-registration failure message: Un-Registration failure

Reset all default value: false

Tag Requirements value: all

Show More Naivagation Values: 10|25|50

Previous Text label: Tidigare

Next Text label: Nästa

Show Text label: Visa:

Seats left Text: Spaces left

No Seats left Text: No spaces left

Text Area Blank copy in Email Template:Ej ifyllt

  

Month Names:Januari,Februari,Mars,April,Maj,Juni,Juli,Augusti,September,Oktober,November,December

  

Month Names Short:Jan,Feb,Mar,Apr,Maj,Jun,Jul,Aug,Sep,Okt,Nov,Dec

  

Day Names:Söndag,Måndag,Tisdag,Onsdag,Torsdag,Fredag,Lördag

  

Day Names Short:Sön,Mån,Tis,Ons,Tor,Fre,Lör

  

Day Names Min:Sö,Må,Ti,On,To,Fr,Lö

  

Date Format:dag/månad/år

  • ASYEVE0001=Event Registration-Portal
  • ASYEVE0002=Watched General Video
  • ASYEVE0003=Watched Virtual Rep Video
  • ASYEVE0004=Watched Patient Video
  • ASYEVE0005=Watched Expert Video
  • ASYEVE0006=Watched Webcast
  • ASYEVE0007=Downloaded Content-Portal
  • ASYEVE0008=Clicked to App Store
  • ASYEVE0009=Watched Learning Module Video
  • ASYEVE0010=eMail Sent
  • ASYEVE0011=eMail Read
  • ASYEVE0012=eMail Clicked
  • ASYEVE0013=Shared a Link
  • ASYEVE0014=Rep Request
  • ASYEVE0015=Joined health.gsk
  • ASYEVE0016=email Not Sent
  • ASYEVE0017=Email Not Sent
  • ASYEVE0018=Email Not Sent
  • ASYEVE0037=IJSFAID is not available
  • ASYEVE0038=EMAIL ID and IJSFAID is not available
  • ASYEVE0039=The user is opted out
  • ASYEVE0040=Scope IDs are different
Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/Sweden/sweden-zejula-jemperli-gynaecological-cancer-summit-on-demand-video-pm-se-nrp-vid-220004.mp4

Zejula produktresumé

Jemperli produktresumé

Webinar | English | 2:51:55

GCD2 Gynaecological Cancer: Debate & Discussion

Inom gynekologisk cancer ser vi förbättrade behandlingsresultat takt med att prediktiva biomarkörer upptäcks och behandlingsmöjligheterna har blivit fler. Debatt och diskussion behövs för att navigera bland dessa nya möjligheter och förbättra vården för patienterna.

Ämnen som berörs är terapier och testning för biomarkörer inom avancerad äggstockscancer och avancerad endometriecancer.

GCD2 Gynaecological Cancer Debate & Discussion

Agenda

00:00 Welcome and Opening Remarks Dr Banerjee – UK
02:03 Introduction: Current landscape of maintenance therapies in advanced ovarian cancer Dr Banerjee – UK
06:15

Plenary Session I: Expert debate on selection of first line maintenance therapies in advanced ovarian cancer

  • 06:15 – Overview of clinical data for PARPi, bevacizumab, and combination therapies (15 minutes)
  • 22:20 – Expert point of view: Why I chose PARPi for 1LM (10 minutes)
  • 40:30 – Expert point of view: Why I chose bevacizumab for 1LM (10 minutes)
  • 53:35 – Case studies and discussion (25 minutes)

Dr Banerjee – UK

Dr Lorusso – IT

Prof Marmé – DE
1:22:00

Plenary Session II: Biomarker testing in advanced ovarian cancer

  • 1:22:05 – Overview of available tests and guidelines (10 minutes)
  • 1:30:25 – Expert point of view: Clinical decision making: the value of HRD testing (10 minutes)
  • 1:42:35 – Expert point of view: Clinical decision making without HRD testing (10 minutes)
  • 1:53:05 – Discussion: Biomarkers in clinical decision making (20 minutes)

Prof Mądry – PL

Dr Marth – AT

Prof Gourley – UK 
1:57:50

Plenary Session III: Expert debate on selection of second line therapies in advanced endometrial cancer

  • 1:57:55 – Endometrial cancer: testing and treatment overview (5 minutes)
  • 2:05:05 – Expert point of view: Considerations for using PD-1 monotherapy in dMMR/MSI-H patients with endometrial cancer (10 minutes)
  • 2:13:00 – Expert point of view: Considerations for using combination therapy in patients with endometrial cancer (10 minutes)
  • 2:28:00 – Case studies and discussion (15 minutes)

Dr Oaknin – ES

Prof Sehouli – DE
2:50:00 Concluding Remarks Dr Oaknin – ES

Medverkande

Dr Susana Banerjee

Dr Susana Banerjee

Medical Oncologist, Gynaecology Unit at The Royal Marsden NHS Foundation Trust, Reader in Women’s Cancers

Dr. med. Frederik Marmé

Professor Dr. med. Frederik Marmé

Head of Conservative Gynaecologic Oncology and Trials Unit, Dpt. Obstetrics and Gynaecology, University Hospital Mannheim

Dr Domenica (Ketta) Lorusso

Dr Domenica (Ketta) Lorusso

Gynaecologic Oncologist, Fondazione Policlinico, Universitario Agostino Gemelli, IRCCSs

Professor Radosław Mądry

Professor Radosław Mądry

Head of Division of Gynaecologic Oncology, Department of Gynaecology Oncology, Chair of Oncology Poznan University of Medical Sciences

Professor Charlie Gourley

Professor Charlie Gourley

Clinical Director, Cancer Research UK Edinburgh Centre

Dr Christian Marth

Dr Christian Marth

Department Head, Department of Obstetrics and Gynaecology, Innsbruck Medical University

Dr Ana Oaknin

Dr Ana Oaknin

Head of Gynaecologic Tumours Unit, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH)

Dr. med. Jalid Sehouli

Professor Dr. med. Jalid Sehouli

Director of the Clinic of Gynaecology, Head of the Interdisciplinary Center of Gynaecological Cancer of the Charité Berlin